Back to Nasopharyngeal Squamous Cell Carcinoma

Nasopharyngeal Squamous Cell Carcinoma — Clinical Trials

MONDO:00060608 active·4 recruitingLast updated: Mar 17, 2026, 7:11 PM

Trial Landscape

Nasopharyngeal Squamous Cell Carcinoma has a growing clinical research program, driven by procedure and drug treatment.

Recruiting

Active Trials

By Approach

Procedure7

Drug Treatment6

Biological Therapy3

2 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Early Phase 1

Phase 1

Phase 2

Phase 3

1 trials are observational or have no phase designation.

Sponsor Types

Academic/Other6NIH2

Trial Locations

United States7 trials

Trials often recruit across multiple countries, so totals exceed the trial count.

8 Trials

Phase 2Recruiting

NCT06636734

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

Sponsor:Emory University

United StatesStarted: Dec 2024Est. completion: Dec 2028Updated: Feb 2026

Phase 2Recruiting

NCT06532279

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Sponsor:NRG Oncology

United StatesStarted: Dec 2024Est. completion: Jan 2027Updated: Feb 2026

Phase 1Recruiting

NCT06868433

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Sponsor:Emory University

United StatesStarted: May 2025Est. completion: Dec 2028Updated: Mar 2026

Not ApplicableRecruiting

NCT06662058

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

Sponsor:Emory University

United StatesStarted: Mar 2025Est. completion: Oct 2029Updated: Apr 2025

Phase 2Not Yet Recruiting

NCT07135804

Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma

Sponsor:Second Affiliated Hospital of Nanchang University

Started: Sep 2025Est. completion: Apr 2031Updated: Aug 2025

Phase 2Active, Not Recruiting

NCT05063552

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Mar 2023Est. completion: Dec 2027Updated: Mar 2026

Phase 1Active, Not Recruiting

NCT03803774

Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Sep 2019Est. completion: Jul 2026Updated: Nov 2025

Early Phase 1Active, Not Recruiting

NCT05245682

Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer

Sponsor:Emory University

United StatesStarted: Feb 2022Est. completion: Jul 2026Updated: Jan 2026

Stay informed about clinical trials for Nasopharyngeal Squamous Cell Carcinoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 17, 2026 at 7:11 PM

Nasopharyngeal Squamous Cell Carcinoma — Clinical Trials

Trial Landscape

By Approach

By Phase

Sponsor Types

Trial Locations

8 Trials

Open Trials5

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma

Active Trials3

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer